Rizatriptan Benzoate
Product Images NDC 53002-1713

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Rizatriptan Benzoate (NDC 53002-1713). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rpk Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl530021713)

The label for Rizatriptan Benzoate 10mg tablets from RPK Pharmaceuticals, Inc. shows a 1-pack carton. It includes instructions to "Take as directed by enclosed patient information sheet or as directed by" a healthcare provider. The label indicates it is an Rx-only medication and includes barcodes, NDC 53002-1713, and space to write patient and clinic information.*

FDA Label Image

Rizatriptan 01

Chemical structure of rizatriptan benzoate displaying the molecular arrangement including the indole and triazole rings, dimethylamino side chain, and benzoate group as a counter ion.*

FDA Label Image

Rizatriptan 02

A line chart depicting the estimated probability of response over time in hours post-dose for placebo, Rizatriptan Benzoate Tablets 5 mg, and Rizatriptan Benzoate Tablets 10 mg. The chart shows comparative effectiveness of the two dosages against placebo within 2 hours after dosing.*

FDA Label Image

Rizatriptan 03

A line graph showing the estimated probability of medication or rescue over 24 hours post-dose for placebo and Rizatriptan Benzoate Tablets at 5 mg and 10 mg doses. The x-axis represents hours post-dose from 0 to 24, and the y-axis shows the estimated probability percentage from 0% to 100%. The graph compares the three groups' responses over time.*

FDA Label Image

Rizatriptan 04

A line graph comparing the percentage (with 95% confidence intervals) over time for Rizatriptan Benzoate orally disintegrating tablets versus placebo. The x-axis represents hours post stage 2 dose, ranging from 0.5 to 2.0 hours, and the y-axis shows the percent response, increasing up to 90 percent. The graph indicates a higher percent response for Rizatriptan Benzoate compared to placebo over time.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.